Codexis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Codexis and other ETFs, options, and stocks.

About CDXS

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. 

CEO
Alison Moore
CEOAlison Moore
Employees
188
Employees188
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
2002
Founded2002
Employees
188
Employees188

CDXS Key Statistics

Market cap
152.55M
Market cap152.55M
Price-Earnings ratio
-2.06
Price-Earnings ratio-2.06
Dividend yield
Dividend yield
Average volume
1.21M
Average volume1.21M
High today
$1.88
High today$1.88
Low today
$1.59
Low today$1.59
Open price
$1.61
Open price$1.61
Volume
4.98M
Volume4.98M
52 Week high
$6.08
52 Week high$6.08
52 Week low
$1.59
52 Week low$1.59

Stock Snapshot

Codexis(CDXS) stock is priced at $1.70, giving the company a market capitalization of 152.55M. It carries a P/E multiple of -2.06.

On 2025-11-08, Codexis(CDXS) stock moved within a range of $1.59 to $1.88. With shares now at $1.70, the stock is trading +6.9% above its intraday low and -9.6% below the session's peak.

Trading activity shows a volume of 4.98M, compared to an average daily volume of 1.21M.

Over the past 52 weeks, Codexis(CDXS) stock has traded between a high of $6.08 and a low of $1.59.

Over the past 52 weeks, Codexis(CDXS) stock has traded between a high of $6.08 and a low of $1.59.

CDXS News

Seeking Alpha 1d
Codexis signals transformation to full-service manufacturing innovator with ECO Synthesis platform and expects 2025 revenue at or above top end of guidance

Earnings Call Insights Codexis signals transformation to full-service manufacturing innovator with ECO Synthesis platform and expects 2025 revenue at or above t...

Codexis signals transformation to full-service manufacturing innovator with ECO Synthesis platform and expects 2025 revenue at or above top end of guidance
TipRanks 2d
Codexis Announces Q3 2025 Results and Strategic Moves

Codexis ( (CDXS) ) has released its Q3 earnings. Here is a breakdown of the information Codexis presented to its investors. Meet Your ETF AI Analyst Discover...

TipRanks 2d
Codexis Faces Uncertainty Amid Leadership Changes and Strategic Shifts, Leading to Hold Rating

Analyst Brendan Smith from TD Cowen maintained a Hold rating on Codexis and decreased the price target to $2.00 from $3.00. Meet Your ETF AI Analyst Discover ho...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

More CDXS News

TipRanks 2d
Codexis reports Q3 EPS (22c), consensus (13c)

Reports Q3 revenue $8.6M, consensus $18.52M. “We’ve had a very exciting and important few months that have set us up very well for the changes we are announcing...

TipRanks 2d
Codexis Announces Workforce Reduction and New CEO

Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...

People also own

Based on the portfolios of people who own CDXS. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.